Title:
c-Src selective reaction monitoring assay
Document Type and Number:
Japanese Patent JP6081912
Kind Code:
B2
Abstract:
Objective quantitation of the c-Src protein directly in cancer patient tissue can aid in determining the aggressiveness of an individual patient's tumor as well as help make more informed decisions about choice of therapy. However, the c-Src protein is currently analyzed directly in formalin fixed patient tissue only by immunohistochemistry methodology which is at best subjectively semi-quantitative. This invention describes an objective quantitative assay for the c-Src protein using mass spectrometry as the analytical methodology. Specific peptides, experimentally discovered characteristics about the peptides, and experimentally established assay conditions based on those peptide characteristics are provided for use in a mass spectrometry-based Selected Reaction Monitoring (SRM) assay in order to measure relative or absolute quantitative levels of c-Src directly in a protein preparation obtained from a formalin fixed cancer patient tissue sample.
Inventors:
David Bee Krisman
Application Number:
JP2013523232A
Publication Date:
February 15, 2017
Filing Date:
July 29, 2011
Export Citation:
Assignee:
EXPRESSION PATHOLOGY, INC.
International Classes:
G01N27/62; C12Q1/37
Foreign References:
| US20090136971 | ||||
| WO2010028658A1 |
Other References:
Yi Chen et al.,"Quantification of β-Catenin Signaling Components in Colon Cancer Cell Lines, Tissue Sections, and Microdissected Tumor Cells using Reaction Monitoring Mass Spectrometry",Journal of Proteome Research,AMERICAN CHEMICAL SOCIETY,2010年 6月30日,V9,pp. 4215-4227,http://pubs.acs.org/doi/abs/10.1021/pr1005197
Attorney, Agent or Firm:
Yukitaka Nakamura
Hirohito Katsunuma
Noritaka Yokota
Hiroshi Sorimachi
Hirohito Katsunuma
Noritaka Yokota
Hiroshi Sorimachi